Band rchd036 was also isolated on the basis of its differential expression 6 hr. after IL-1 treatment (FIG.16). Northern analysis (FIG.17) revealed an 8 kb band which was up-regulated 6 hr. after IL-1 treatment. Another Northern analysis was performed testing rchd036 under the shear stress condition of Paradigm D, which are described in the example in Section 9, below. Interestingly, rchd036 is not induced by shear stress, as indicated by the lack of any band after either 1 hr. or 6 hr. of treatment (FIG.33). This result provides an example of an IL-1-inducible endothelial cell gene that is not regulated by shear stress, indicating that these induction pathways can be separated, and may provide for drugs with greater specificity for the treatment of inflammation and atherosclerosis. The DNA sequence was obtained from subclones of amplified DNA (FIG.18) (SEQ ID NO. 4), and a search of the database revealed no sequence similarities. A PCR amplification experiment determined that the rchd036 gene is located on human chromosome 15.

Page 128, lines 23 through 27:

Determination of chromosomal location was carried out according to the method described in Section 6.1.3, above. The primers used for rchd523 were (for-atgccgtgtgggttagtc)(SEQ ID NO. 28) and (rev-attttatgggaaggtttttaca)(SEQ ID NO. 29) ; and for rchd534 were (for-cttttctgcgtctcccat) and (rev-agacatcagaaactccaacc).

IN THE CLAIMS

A marked up version of the claims showing the amendments is attached hereto as Exhibit A. A clean version of all pending claims as amended herein is attached hereto as Exhibit B.

Please cancel claims 1-3, 8, and 10-11, without prejudice.

Please add new claims 67-102 as follows:

67. (New) An antibody which immunospecifically binds to the amino acid sequence of Figure 28.

68. (New) An antibody composition according to claim 67, wherein said antibody is a polyclonal antibody.

69. (New) An antibody composition according to claim 67, wherein said antibody is a monoclonal antibody.

70. (New) An antibody composition according to claim 67, wherein said antibody is a conjugated monoclonal antibody.

71. (New) An antibody composition according to claim 67, wherein said antibody is detectably labeled.

72. (New) An antibody composition according to claim 71, wherein said detectable label is selected from the group consisting of fluorescent labeling compounds, bioluminescent compounds and radioisotopes or any combination thereof.

73. (New) A composition for administration to patients comprising an antibody according to claim 67 together with a physiologically acceptable diluent or carrier.

74. (New) A composition according to claim 73, which is adapted for intravenous administration.

75. (New) A composition according to claim 73, which additionally comprises another therapeutic antibody.

76. (New) An antibody which immunospecifically binds to one or more of the extracellular domains, or portions and/or analogs thereof of the rchd523 amino acid sequence of Figure 28.

77. (New) An antibody composition according to claim 76, wherein said antibody is a polyclonal antibody.

78. (New) An antibody composition according to claim 76, wherein said antibody is a monoclonal antibody.

79. (New) An antibody composition according to claim 76, wherein said antibody is detectably labeled.

80. (New) An antibody composition according to claim 79, wherein said detectable label is selected from the group consisting of fluorescent labeling compounds, bioluminescent compounds and radioisotopes or any combination thereof.

81. (New) A composition for administration to patients comprising an antibody according to claim 76 together with a physiologically acceptable diluent or carrier.

82. (New) A composition according to claim 81, which is adapted for intravenous administration.

83. (New) A composition according to claim 81, which additionally comprises another therapeutic antibody.

84. (New) An antibody which immunospecifically binds to one or more of the extracellular domains, or portions and/or analogs thereof of the rchd523 amino acid sequence of Figure 28, wherein the extracellular domain analog is an Ig-tailed soluble fusion protein.

85. (New) An antibody composition according to claim 84, wherein said antibody is a polyclonal antibody.

86. (New) An antibody composition according to claim 84, wherein said antibody is a monoclonal antibody.

87. (New) An antibody composition according to claim 84, wherein said antibody is detectably labeled.

88. (New) An antibody composition according to claim 87, wherein said detectable label is selected from the group consisting of fluorescent labeling compounds, bioluminescent compounds and radioisotopes or any combination thereof.

89. (New) A composition for administration to patients comprising an antibody according to claim 84 together with a physiologically acceptable diluent or carrier.

90. (New) A composition according to claim 89, which is adapted for intravenous administration.

91. (New) A composition according to claim 89, which additionally comprises another therapeutic antibody.

92. (New) An antibody which immunospecifically binds to the gene product encoded by a polynucleotide up-regulated in endothelial cells under increased shear stress, wherein said polynucleotide hybridizes under highly stringent conditions to the complement of (a) the polypeptide coding region from nucleotide residue number 559 to 1683 of SEQ ID NO:6; or (b) the polypeptide coding region of the cDNA contained in plasmid pFCHD523, as deposited with the Agricultural Research Service Culture Collection as Accession Number B-21458, wherein said highly stringent conditions comprise hybridization in 0.5M NaHPO4, 7% sodium dodecyl sulphate (SDS), 1 mM EDTA at 65C, and washing in 0.1X SSC / 0.1% SDS at 68C.

93. (New) An antibody composition according to claim 92, wherein said antibody is a polyclonal antibody.

94. (New) An antibody composition according to claim 92, wherein said antibody is a monoclonal antibody.

95. (New) An antibody composition according to claim 92, wherein said antibody is detectably labeled.

96. (New) An antibody composition according to claim 95, wherein said detectable label is selected from the group consisting of fluorescent labeling compounds, bioluminescent compounds and radioisotopes or any combination thereof.

97. (New) A composition for administration to patients comprising an antibody according to claim 92 together with a physiologically acceptable diluent or carrier.

98. (New) A composition according to claim 97, which is adapted for intravenous administration.

99. (New) A composition according to claim 97, which additionally comprises another therapeutic antibody.

100. (New) A method for treating a human patient having a cardiovascular symptom, which comprises administering an antibody according to any one of the claims 67, 76, 84, or 92, wherein said cardiovascular symptom is atherosclerosis, restinosis, or ischemia/reperfusion or any combination thereof, wherein said cardiovascular symptom is ameliorated.

101. (New) A method according to claim 100, wherein the antibody is administered intravenously.

102. (New) A method according to claim 100, wherein the antibody is administered together with another therapeutic antibody.

IN THE SEQUENCE LISTING

Applicants have received a Notice to Comply With Requirements For Patent Applications Containing Nucleotide Sequence And/Or Amino Acid Sequence Disclosures (hereinafter, "Notice to Comply"), dated December 18, 2001, in connection with the above-identified application. In response to the Notice, Applicant submits herewith a Sequence

Listing in computer readable form pursuant to 37 C.F.R. §1.821 (c), (d) and (e), respectively.

Pursuant to 37 C.F.R. § 1.821(f), the undersigned attorney for Applicants hereby states that the copy of the Sequence Listing in computer readable form submitted in accordance with 37 C.F.R. §1.821 (c), (d) and (e), respectively herewith is the same as the paper copy of the Sequence Listing submitted at the time of filing of this application. I hereby state that the submission herein under 37 C.F.R. §1.821(g) does not include new matter.